Navigation Links
IRIDEX Reports 2013 First Quarter Results
Date:5/2/2013

o the size and growth of and trends in the markets in which the Company operates, including market adoption of new technologies; the success of the Company's development, marketing and sales efforts, including the adoption of MicroPulse laser therapy devices; the Company's growth strategy; the Company's acquisition strategy; the Company's sales revenue growth, operational plans, and profitability expectations; the Company's projected fiscal 2013 financial results; and the Company's share repurchase program. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 29, 2012 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

TABLES FOLLOW

 IRIDEX Corporation

Condensed Consolidated Statements of Operations

(In thousands, except per share data)(unaudited)Three Months EndedMarch 30,March 31, 20132012Total revenues

$
8,939$
8,305Cost of revenues

4,7084,319Gross profit

4,2313,986Operating expenses:Research and development

9961,182Sales and marketing

1,6251,864General and administrative

1,1861,176Proceeds from demutualization of insurance carrier

(473)-Total operating expenses

3,3344,222Income (loss) from continuing operations

897(236)  Other expense, net

(18)(27)Income (loss) from continuing operations before provision for income taxes

879(263)Provision for income taxes

52  Income (loss) from continuing operations, n
'/>"/>

SOURCE IRIDEX Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. IRIDEX Announces Receipt of Large Orders for Laser Systems from Developing Countries
2. IRIDEX Announces First Quarter 2013 Conference Call and Release Date
3. IRIDEX Announces Global Distribution and Supply Agreement with Peregrine Surgical, Ltd.
4. IRIDEX Reports Record 2012 Fourth Quarter Results
5. IRIDEX Announces Fourth Quarter and Full Year 2012
6. IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
7. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
8. IRIDEX Announces FDA 510(k) and CE Clearance of New Laser Delivery System for Fast, Non-invasive Treatment of Serious Retinal Diseases
9. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
10. IRIDEX Announces Tender Offer to Purchase up to 487,500 Shares of its Common Stock
11. IRIDEX Reports 2012 Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 Company ... programming expertise to big data, aerospace and defense, ... eInfochips, a leading engineering R&D services company, today ... NVIDIA GPU-powered solutions for aerospace and defense ... (HPC), industrial , and visual ...
(Date:7/29/2014)... Israel , July 30, 2014 /PRNewswire/ ... Premier, Stockholm : "IMNP."; "Immune" or ... screening of patients for a Phase II proof of ... bertilimumab in the treatment of moderate to severe bullous ... will receive two bertilimumab infusions, at a dose of ...
(Date:7/29/2014)... Amgen (NASDAQ: AMGN ) today announced financial ... include: , Total revenues increased 11 percent to ... by strong performance across the portfolio, particularly Enbrel ® ... (denosumab) and XGEVA ® (denosumab). , Adjusted ... revenues and a significant increase in the profitability of ...
Breaking Medicine Technology:eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
(Date:7/30/2014)... (PRWEB) July 30, 2014 BuyCBDOnline.co ... infused products, is pleased to announce that it is ... selection of top quality products available for immediate shipping. ... still in it's infancy stages," site founder Jason Liss ... already a wide variety of unique products that are ...
(Date:7/30/2014)... 2014 The Independent Woman , ... holding 5 free financial workshops in the San Francisco ... goal of these workshops is our collective success, linking ... financial empowerment. , These workshops were designed by women, ... successful investor, entrepreneur, and bestselling author (Rich Woman and ...
(Date:7/30/2014)... July 30, 2014 With the ... of personal health expenditure as well as the ... system, China diagnostic reagent industry has been developing ... 90%. In 2013, Chinese in vitro diagnostics market ... came from in vitro diagnostic reagents. , ...
(Date:7/30/2014)... According to the Yeast Infection No More book ... that will help candida sufferers get rid of their ... uncovers to readers the truth about yeast infection and the ... people will discover natural and safe remedies to relieve symptoms ... and irritation of the vagina or vulva. , Vkool ...
(Date:7/30/2014)... 30, 2014 My Clients Plus ... 80 different electronic therapy note templates. Healthcare providers ... other computing devices all while meeting the HIPPA ... electronic medial records (EMR) consist of psychological intake ... essential categories. SOAP and DAP note formats ...
Breaking Medicine News(10 mins):Health News:Delicious, Unique CBD-Rich Hemp Oil Product Debuts from BuyCBDOnline.co 2Health News:Delicious, Unique CBD-Rich Hemp Oil Product Debuts from BuyCBDOnline.co 3Health News:The Independent Woman is Coming to the San Francisco Area in August - Women Helping Women Reach Their Financial Goals 2Health News:The Independent Woman is Coming to the San Francisco Area in August - Women Helping Women Reach Their Financial Goals 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 2Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 4Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 2Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 3Health News:My Clients Plus Announces Over 80 Online Therapy Notes to Help Healthcare Providers Go Paperless 2
... reports of persistent,recent-onset symptoms linked to ovarian cancer ... full quickly and abdominal bloating -- when,combined with ... detection of,ovarian cancer by 20 percent, according to ... Center published online today in CANCER., Research ...
... inflammatory rheumatic disease, associated with stiffening of the vertrebral ... diagnosed in Germany, but milder forms of the disease ... Dr. Roland R. Wick, with Dr. Elke A. Nekolla, ... Dr. Wolfgang Gssner have conducted a long-term follow-up study ...
... Oral cannabis may even cause increased sensitivity in certain ... -- Oral cannabis (a form of medical marijuana) was ... actually increased sensitivity to some other kinds of discomfort, ... , Their study included 18 healthy women who ...
... might extend the effectiveness of clot-busting tPA, researchers say ... weapon against cancer might also boost stroke patients, survival, ... "wonder drug" against cancers such as chronic myelogenous leukemia ... boost the effectiveness and limit the side effects of ...
... More younger people than before are expected to ... acid in 2008, according to Millennium Research Group, ... Group (MRG),conducted a detailed survey focused on facial ... conference in San Antonio, Texas.,Over 60 US-based dermatologists ...
... $0.96 to $0.97 - - ... - Announces Additional ... Nash Corporation,(Nasdaq: KNSY ) today updated and expanded its previously announced ... to,include earnings per share estimates. In addition, the Company provided an,outlook for ...
Cached Medicine News:Health News:Symptom Screening Plus a Simple Blood Test Equals a 20 Percent Jump in Early Detection of Ovarian Cancer 2Health News:Symptom Screening Plus a Simple Blood Test Equals a 20 Percent Jump in Early Detection of Ovarian Cancer 3Health News:Increased cancer risk following the use of radioactive Radium-224 in the therapy 2Health News:Medical Pot Ineffective as Acute Pain Treatment 2Health News:Cancer Drug Gleevec Could Fight Stroke 2Health News:Cancer Drug Gleevec Could Fight Stroke 3Health News:Younger Patients Seeking More Aesthetic Treatments 2Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 2Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 3Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 4Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 5Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 6Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 7Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 8Health News:Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance 9
Khosla Precision and Quality in Medical and Surgical Products....
...
...
To enter, dissect, elevate and smooth the flap. Combined features of Spatula, Dissector and Forceps. - Also available in Titanium...
Medicine Products: